ADDI.OB ... onfire...

[fill_the_gap]

For more information please visit our website www.addisondavis.com or contact Matt Maguire 1-866 THE APPL(E).

The same Consulting Firm that represents HISC.

[J.Livermore]

I'm away from office, can anyone post a chat ? it's forming a nice triangle !

[Ramsburg]

Yes...

Ignoring highs and spikes, we can plot a nice Ascending Triangle...
Volume bar today, could be considered Bullish, showing that money is coming back to this stock on a rising day...

I'm looking forward for tomorrow's session

Regards !

[evgeny05]

Hi !

Addison-Davis Receives $750,000 USD to Finance "Parents' Tool" Drug Test Program
Sep 23, 2005 8:30:00 AM
WESTLAKE VILLAGE, CA -- (MARKET WIRE) -- 09/23/05 -- Addison-Davis Diagnostics, Inc. (OTC BB: ADDI) is pleased to announce that they have received funding from their $750,000 financing.

The proceeds from the funding will be utilized to further its over the counter sales program for the "Parents' Tool" Drug Test Program and its Drug Stop product with the goal of a national distribution campaign. Addison-Davis will also be implementing the "Parents' Tool" interactive web portal which will allow parents to log on to chat, look up information, find local programs, and even post blogs all designed to help keep their children drug-free.

"We are very excited about getting this web portal up and running. The monies we received will enable us to execute our business plan and produce real results for our shareholders," stated Edward W. Withrow III, CEO of Addison-Davis.

The "Parents' Tool" Drug Test, a self-contained NIDA (National Institute of Drug Abuse) 5-panel drug test is to be marketed by national retail chains throughout the United States. The "Parents' Tool" drug test will screen for Amphetamines (Crystal Meth), Cocaine, Opiates, Phencyclidine (PCP) and Marijuana (THC

[evgeny05]

Hi !

ADDI - UP 26%



Good luck.
Evgeny.

[evgeny05]

Hi !

MA (50) - 0.051
MA (200) - 0.036

Bullish Engulfing !



Good luck.
Evgeny.

[evgeny05]

SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 12b-25

                        Commission File Number 000-25022

                           NOTIFICATION OF LATE FILING

|X|  Form 10-K     |_|  Form 11-K      |_|  Form 20-F         |_|  Form 10-Q
|_|  Form N-SAR

                         For Period Ended: June 30, 2005

|_|  Transition Report on Form 10-K     |_|  Transition Report on Form 10-Q

|_|  Transition Report on Form 20-F     |_|  Transition Report on Form N-SAR

     For the Transition Period Ended: __________________________________________

      Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

      If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:_________________________

                                     PART I
                             REGISTRANT INFORMATION

Full name of registrant                  Addison-Davis Diagnostics, Inc.
Former name if applicable
Address of principal executive office    143 Triunfo Canyon Road, Suite 104
City, state and zip code                 Westlake Village, California 91361


                                     PART II
                             RULE 12b-25 (b) AND (c)

      If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the
following should be completed. (Check box if appropriate.)

   |  (a)   The reasons described in reasonable detail in Part III of this form
   |        could not be eliminated without unreasonable effort or expense;
   |  (b)   The subject annual report, semi-annual report, transition report on
   |        Form 10-K, 20-F, 11-K or Form 10-Q, or portion thereof will be filed
|X||        on or before the 15th calendar day following the prescribed due
   |        date; or the subject quarterly report or transition report on Form
   |        10-Q, or portion thereof will be filed on or before the fifth
   |        calendar day following the prescribed due date; and
   |  (c)   The accountant's statement or other exhibit required by Rule
   |        12b-25(c) has been attached if applicable.


<PAGE>

                                    PART III
                                    NARRATIVE

      State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F,
10-Q, N-SAR or the transition report portion thereof could not be filed within
the prescribed time period.

      The registrant is in the process of preparing and reviewing the financial
information of the Company on a consolidated basis. The process of compiling and
disseminating the information required to be included in the Form 10-KSB for the
relevant fiscal year, as well as the completion of the required review of the
Company's financial information on a consolidated basis, could not be completed
without incurring undue hardship and expense. The registrant undertakes the
responsibility to file such annual report no later than fifteen days after its
original date.


                                     PART IV
                                OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this
notification

Edward W. Withrow III                  (805)                      494-7838
        (Name)                      (Area Code)              (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).

                               |X|  Yes      |_|  No


(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?

                               |X|  Yes      |_|  No

If so: attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

      For the year ended June 30, 2004, the registrant had revenues of
approximately $192,109 and a net loss of approximately $(7,092,912). For the
year ended June 30, 2005, the registrant currently estimates that it had
revenues of approximately $5,176 and a net loss of approximately $(2,817,226).
Results for this relevant fiscal year remain subject to further adjustment and
actual results may differ significantly from the foregoing estimates.


<PAGE>

                         Addison-Davis Diagnostics, Inc.
                   Name of Registrant as Specified in Charter.

Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.

Date: September 29, 2005                 By: /s/ Edward W. Withrow III
                                             -----------------------------------
                                             Edward W. Withrow III
                                             Chief Executive Officer
</TEXT>
</DOCUMENT>



SCHEDULE 14C

                                 (RULE 14C-101)

Information Statement Pursuant to Section 14(c) of the Securities Exchange Act
of 1934

Check the appropriate box:

|_|   Preliminary Information Statement

|X|   Definitive Information Statement

|_|   Confidential, for Use of the Commission Only (as permitted by Rule
      14c-5(d)(2))


                         ADDISON-DAVIS DIAGNOSTICS, INC.

                (Name of Registrant As Specified In Its Charter)


Payment of Filing Fee (Check the Appropriate Box):

|X|   No fee required

|_|   Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

      (1)   Title of each class of securities to which transaction applies:

      (2)   Aggregate number of securities to which the transaction applies:

      (3)   Per unit price or other  underlying  value of  transaction  computed
            pursuant  to  Exchange  Act Rule 0-11 (Set forth the amount on which
            the filing fee is calculated and state how it was determined):

      (4)   Proposed maximum aggregate value of transaction:

      (5)   Total fee paid:


|_|   Fee paid previously with preliminary materials

|_|   check box if any part of the fee is offset as  provided  by  Exchange  Act
Rule  0-11(a)(2)  and identify the filing for which the  offsetting fee was paid
previously.  Identify the previous filing by registration  statement  number, or
the Form or Schedule and the date of its filing.

      (1)   Amount previously paid:

      (2)   Form, Schedule or Registration Statement No.:

      (3)   Filing Party:

      (4)   Date Filed:


<PAGE>

                         ADDISON-DAVIS DIAGNOSTICS, INC.
                       143 TRIUNFO CANYON ROAD, SUITE 104
                           WESTLAKE VILLAGE, CA 91361

                              INFORMATION STATEMENT
                             PURSUANT TO SECTION 14
                     OF THE SECURITIES EXCHANGE ACT OF 1934
                 AND REGULATION 14C AND SCHEDULE 14C THEREUNDER

WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE NOT  REQUESTED  TO SEND US A PROXY
THE ACTIONS  DESCRIBED  BELOW HAVE ALREADY BEEN  APPROVED BY WRITTEN  CONSENT OF
HOLDERS OF A  MAJORITY  OF  OUTSTANDING  SHARES OF COMMON  STOCK.  A VOTE OF THE
REMAINING STOCKHOLDERS IS NOT NECESSARY.

                               September 29, 2005
                              Westlake Village, CA

This information statement has been mailed on or about September 29, 2005 to the
stockholders  of record on July 12, 2005 (the  "Record  Date") of  Addison-Davis
Diagnostics, Inc., a Delaware Company (the "Company") in connection with certain
actions to be taken by the written  consent of the majority  stockholders of the
Company,  dated as of July 12,  2005.  The  actions to be taken  pursuant to the
written  consent  shall be taken on or about October 19, 2005, 20 days after the
mailing of this information statement.

THIS IS NOT A NOTICE OF A SPECIAL  MEETING OF  STOCKHOLDERS  AND NO  STOCKHOLDER
MEETING WILL BE HELD TO CONSIDER ANY MATTER WHICH WILL BE DESCRIBED HEREIN.

                       By Order of the Board of Directors,


                            /s/ Edward W. Withrow III


                            CEO, Director


<PAGE>

                          NOTICE OF ACTION TO BE TAKEN
                                 PURSUANT TO THE

                    WRITTEN CONSENT OF MAJORITY STOCKHOLDERS
                IN LIEU OF A SPECIAL MEETING OF THE STOCKHOLDERS
                              DATED JULY 1 2, 2005

To Our Stockholders:

NOTICE IS HEREBY GIVEN that the following  action will be taken  pursuant to the
written consent of a majority of stockholders  dated July 12, 2005, in lieu of a
special  meeting of the  stockholders.  Such  actions  will be taken on or about
October 19, 2005:

1. The Company  will amend its  certificate  of  incorporation  to decrease  the
authorized  amount of common stock from  5,000,000,000  shares to  2,000,000,000
shares.

                      OUTSTANDING SHARES AND VOTING RIGHTS

As of the Record Date,  the  Company's  authorized  capitalization  consisted of
5,000,000,000  shares  of common  stock,  par value  $.001 per  share,  ("Common
Stock") of which 36,275,219  shares were issued and outstanding as of the Record
Date.  Holders  of Common  Stock of the  Company  have no  preemptive  rights to
acquire or subscribe to any of the additional shares of Common Stock.

Each  share of Common  Stock  entitles  its  holder  to one vote on each  matter
submitted to the stockholders.  However, because stockholders holding at least a
majority of the voting rights of all  outstanding  shares of capital stock as of
the Record  Date have voted in favor of the  foregoing  proposal  by  resolution
dated July 12, 2005, and having sufficient voting power to approve such proposal
through their ownership of capital stock, no other stockholder  consents will be
solicited in connection with this Information Statement.

Pursuant to Rule 14c-2 under the  Securities  Exchange Act of 1934,  as amended,
the proposal will not be adopted until a date at least 20 days after the date on
which  this  Information  Statement  has been  mailed to the  stockholders.  The
Company anticipates that the actions  contemplated herein will be effected on or
about the close of business on October 19, 2005.

The Company has asked brokers and other custodians,  nominees and fiduciaries to
forward this Information  Statement to the beneficial owners of the Common Stock
held of record by such persons and will reimburse such persons for out-of-pocket
expenses incurred in forwarding such material.

This Information Statement will serve as written notice to stockholders pursuant
to Regulation 14C, and Section 228(e) of the Delaware General Corporation Law.


<PAGE>

                 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS



The following table sets forth, as of July 12, 2005, certain information
regarding the ownership of Addison-Davis Diagnostics, Inc.'s capital stock by:

      o     each director and executive  officer of  Addison-Davis  Diagnostics,
            Inc.;

      o     each person who is known to Addison-Davis Diagnostics,  Inc. to be a
            beneficial  owner  of more  than 5% of any  class  of  Addison-Davis
            Diagnostics, Inc.'s voting stock; and

      o     by all officers and directors of Addison-Davis Diagnostics,  Inc. as
            a group.

Unless  otherwise   indicated  below,  to  Addison-Davis   Diagnostics,   Inc.'s
knowledge,  all persons  listed below have sole voting and investing  power with
respect to their  shares of capital  stock,  except to the extent  authority  is
shared by spouses under applicable community property laws.

Beneficial  ownership  is  determined  in  accordance  with  the  rules  of  the
Securities and Exchange  Commission and generally  includes voting or investment
power with respect to  securities.  Shares of common  stock  subject to options,
warrants or convertible  securities exercisable or convertible within 60 days of
July 12, 2005 are deemed  outstanding for computing the percentage of the person
or entity holding such options,  warrants or convertible  securities but are not
deemed  outstanding  for  computing the  percentage of any other person,  and is
based on 36,275,219 shares issued and outstanding.

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------
                                      Name and Address                                            Percent
  Title of                                  Of                        Amount and Nature              Of
   Class                            Beneficial Owners (1)            Of Beneficial Ownership       Class
------------------------------------------------------------------------------------------------------------
<S>                                <C>                                    <C>                       <C>
Common Stock                       Edward W. Withrow III                  6,188,912                 17.38%
------------------------------------------------------------------------------------------------------------
Common Stock                       Fred De Luca                           1,702,266                  4.78%
------------------------------------------------------------------------------------------------------------
Common Stock                       All officers and directors             7,891,178                 22.16%
                                   As a group (two persons)
------------------------------------------------------------------------------------------------------------
</TABLE>

(1) Unless otherwise noted, the address for each of the named beneficial  owners
is 143 Triunfo Canyon Road, Suite 104 Westlake Village, California 91361.

                                CHANGE IN CONTROL

To the knowledge of management,  there are no present arrangements or pledges of
securities  of the  Company,  which may  result in a change  in  control  of the
Company.


<PAGE>

                         DISSENTER'S RIGHTS OF APPRAISAL

The stockholders have no dissenter's rights of appraisal.

                   AMENDMENT TO THE ARTICLES OF INCORPORATION

On July 12,  2005,  the  majority  stockholders  of the  Company  authorized  an
amendment to the Company's  certificate of  incorporation to decrease the number
of authorized shares of common stock from  5,000,000,000 to  2,000,000,000.  The
Company currently has authorized capital stock of 5,000,000,000 shares of common
stock and approximately  36,275,219 shares of common stock are outstanding as of
the Record Date. The Board believes that the decrease in authorized shares would
still  provide the Company with a sufficient  amount of  authorized  shares with
respect to the Company's capital structure.

               REASON FOR THE DECREASE IN AUTHORIZED COMMON STOCK

This amendment will not alter the current number of issued shares.  The relative
rights and  limitations  of the shares of common  stock would  remain  unchanged
under this proposal.

The decrease in the number of  authorized  but  unissued  shares of common stock
would adequately enable the Company,  without further stockholder  approval,  to
issue shares from time to time as may be required for proper business  purposes,
such as raising  additional capital for ongoing  operations,  business and asset
acquisitions,  stock splits and dividends,  present and future employee  benefit
programs and other corporate purposes.

The proposed  decrease in the authorized  number of shares of Common Stock could
have a number of effects on the Company and it's stockholders depending upon the
exact nature and circumstances of any actual issuance of authorized but unissued
shares.  Primarily,  the proposed decrease in the authorized number of shares of
Common  Stock  would more  accurately  represent,  and be more in line  with,  a
realistic  capital  structure  for a  company  of our  size.  Additionally,  the
proposed  decrease  in the  authorized  number of shares of Common  Stock  would
prevent a disproportionately high franchise tax by lowering the Company's annual
Delaware  franchise  tax  obligations.  The  Board  believes  that  the  capital
structure modifications and financial benefits offered by the amendment outweigh
any disadvantages.


<PAGE>

                             ADDITIONAL INFORMATION

The  Company is  subject to the  informational  requirements  of the  Securities
Exchange  Act of 1934,  as  amended  (the  "Exchange  Act"),  and in  accordance
therewith files reports, proxy statements and other information including annual
and quarterly  reports on Form 10-KSB and 10-QSB (the "1934 Act  Filings")  with
the Securities and Exchange  Commission  (the  "Commission").  Reports and other
information  filed by the  Company  can be  inspected  and  copied at the public
reference  facilities  maintained  at the  Commission  at Room  1024,  450 Fifth
Street, N.W., Washington, DC 20549. Copies of such material can be obtained upon
written request addressed to the Commission, Public Reference Section, 450 Fifth
Street,  N.W.,  Washington,  D.C.  20549,  at prescribed  rates.  The Commission
maintains a web site on the Internet (http://www.sec.gov) that contains reports,
proxy and information  statements and other  information  regarding issuers that
file  electronically  with the Commission through the Electronic Data Gathering,
Analysis and Retrieval System ("EDGAR").

The  following  documents  as  filed  with the  Commission  by the  Company  are
incorporated herein by reference:

1. Annual Report on Form 10-KSB for the year ending June 30, 2004; and

2. Quarterly Report on Form 10QSB for the period ending March 31, 2005

The Company will furnish a copy of any exhibit thereto or other information upon
request by a  stockholder  to the  Company's  principal  offices at 143  Triunfo
Canyon Road, Suite 104 Westlake Village, CA 91361, attn: Edward W. Withrow III

                      By Order of the Board of Directors,


                            /s/ Edward W. Withrow III


                            CEO, Director


Westlake Village, CA
September 29, 2005


<PAGE>

[evgeny05]

 

[evgeny05]

Addison-Davis Diagnostics, Inc. (ADDI) primarily offers diagnostic products. Its diagnostic platform is designed for point-of-care and ambulatory use, and incorporates a single-use disposable specimen collection device. The company's desktop analyzer is capable of detecting data for Myoglobin, CK-MB, Cardiac Troponin-1, and GP-BB, as well as the presence and volume of cocaine. The analyzer can be used in clinics and doctor's offices, as well as in emergency rooms. Addison-Davis is also developing a hand-held mobile multiple assay analyzer that would incorporate the patented technology for specimen collection and provide results for various cardiac and blood-born metrics. In addition, the company engages in the development and commercialization of Drug Stop, a FDA cleared rapid urinalysis test for drugs of abuse, for professional and over-the-counter use. The company was formerly known as QT 5, Inc. and changed its name to Addison-Davis Diagnostics, Inc. in November 2004. Addison-Davis is based in Westlake Village, California. With 66.99 million shares outstanding and an undisclosed short position, there is no longer a failure to deliver in shares of ADDI.

[evgeny05]

Hi

If ADDI will break 0.0057 $ without problems will go till 0.01 $. I have risked and have bought on 1000 $. I like to buy actions which lay on a floor.

Good luck.

[evgeny05]

Hi
Look ARON end MFI - accumulation

[evgeny05]

Hi
Today ADDI has broken 0.0057 $, probably it has begun interesting game 

[evgeny05]

Hi
It is broken 0.006 ADDI goes on the north
Good luck

[evgeny05]

Hi
Good volume
but resistance 0.009 is not broken, if tomorrow ADDI does not break 0.009 I sell (only my opinion)
Good luck.

[evgeny05]

HI
Resistance 0.007, the following 0.009, I think ADDI will try to break resistance (only my opinion)